BioLife Solutions, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Activists also report to the SEC on BioLife Solutions, Garrett Motion, Life Time Group Holdings, Infleqtion, and CBL Properties.
Why BioLife Solutions (BLFS) is on investors’ radar BioLife Solutions (BLFS) has drawn attention after recent share price moves, with the stock up about 21% over the past month and roughly 3% in the past 3 months. For investors tracking the cell and gene therapy supply chain, these returns, together with annual revenue of US$96.2 million and a reported net loss of US$12.13 million, raise questions about how the stock is being valued today. See our latest analysis for BioLife Solutions. At a...
Good afternoon, everyone, and thank you for joining us for BioLife's First Quarter 2026 Conference Call. Performance in the quarter was driven by continued strength across our broader product portfolio, led by our biopreservation media or BPM franchise. At the same time, we're seeing continued momentum across the CGT landscape, driven by expansion into larger indications, encouraging data readouts, strategic M&A and an improving funding environment, all of which we believe will support long-term growth across our end markets and underpins sustained value creation for BioLife shareholders.
Moby summary of BioLife Solutions, Inc.'s Q1 2026 earnings call
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDTCompany ParticipantsTroy Wichterman - Chief Financial OfficerRoderick de Greef -...
Presentation Operator MessageOperator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q1 2026 Shareholder and Analyst Conference Call.
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +700.00% and +7.78%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions (NASDAQ:BLFS) reported first-quarter 2026 revenue of $27.5 million, up 25% year-over-year, as management pointed to continued strength in its biopreservation media (BPM) franchise and growing contribution from its broader cell processing tools portfolio. CEO and Chairman Roderick
BioLife Solutions Q1 2026 earnings beat estimates with $27.5M revenue and $0.04 EPS, achieving GAAP profitability and 25% revenue growth, boosting shares 9.7%.
The United States market has seen a robust performance, climbing 3.2% in the last week and rising 31% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors looking to capitalize on undervalued assets.
Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP...
The United States market has shown robust growth, with a 3.2% increase over the past week and a remarkable 31% rise over the last year, while earnings are anticipated to grow by 16% annually. In this environment, identifying stocks that are trading below their estimated value can offer investors potential opportunities for gains amidst overall market optimism.
Quanterix (QTRX) delivered earnings and revenue surprises of -25.81% and -0.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
The United States market has shown robust growth, with a 1.8% increase over the last week and a remarkable 30% rise in the past year, while earnings are projected to grow by 16% annually. In such an environment, identifying stocks that are significantly undervalued relative to their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 BOTHELL, Wash., April 23, 2026 /PRNewswire / -- BioLife Solutions, Inc. , a...
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioLife Solutions, Inc. reported past fourth-quarter 2025 sales of US$24.76 million versus US$20.72 million a year earlier, with full-year 2025 revenue of US$96.21 million and a reduced net loss of US$4.60 million after its business refocus. The company also issued 2026 guidance calling for higher revenue and GAAP profitability, highlighting progress from its transformation toward higher-margin, recurring cell processing products and new collaborations. With management now targeting revenue...
Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 1.58M | $30.09M | 0.00% | Added+4.7% | 2026-03-31 |
| FidelityFMR | fundamental | 1.47M | $28.05M | 0.00% | Trimmed-5.0% | 2026-03-31 |
| RenTech | quant | 207.1K | $3.95M | 0.01% | Trimmed-7.8% | 2026-03-31 |
| DEShaw | quant | 101.9K | $1.94M | 0.00% | Trimmed-38.8% | 2026-03-31 |
| TRowePrice | fundamental | 40.3K | $769 | 0.00% | Added+35.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 0.06 | — | — |
| 2026-05-07 | 0.02 | 0.04 | +160.95% |
| 2026-02-26 | 0.01 | 0.04 | +680.00% |
| 2025-11-06 | -0.01 | 0.01 | +200.00% |
| 2025-08-07 | -0.01 | 0.01 | +220.00% |
| 2025-05-08 | -0.04 | 0.04 | +201.43% |
| 2025-03-03 | -0.06 | -0.02 | +71.77% |
| 2024-11-12 | -0.05 | -0.02 | +62.50% |
| 2024-08-08 | -0.09 | -0.05 | +45.68% |
| 2024-05-09 | -0.20 | -0.20 | -0.05% |
| 2024-02-29 | -0.27 | -0.21 | +21.68% |
| 2023-11-09 | -0.28 | -0.34 | -20.76% |
| 2023-08-08 | -0.18 | -0.24 | -33.39% |
| 2023-05-10 | -0.16 | -0.27 | -62.20% |
| 2023-03-16 | -0.12 | -0.19 | -59.01% |
| 2022-11-09 | -0.10 | -0.15 | -48.94% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BLFS | +17.49% | +23.55% | +3.06% | +13.89% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +14.52% | +28.19% | +6.50% | +1.21% |